Oncoscience GmbH

Industry / private company


Location: Schenefeld, Germany (DE) DE

A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma (2015) Westphal M, Heese O, Steinbach JP, Schnell O, Schackert G, Mehdorn M, Schulz D, et al. Journal article